{"id":"https://openalex.org/W4392724027","doi":"https://doi.org/10.1158/0008-5472.c.6510510","title":"Data from ErbB3 Targeting Enhances the Effects of MEK Inhibitor in Wild-Type BRAF/NRAS Melanoma","display_name":"Data from ErbB3 Targeting Enhances the Effects of MEK Inhibitor in Wild-Type BRAF/NRAS Melanoma","publication_year":2023,"publication_date":"2023-03-31","ids":{"openalex":"https://openalex.org/W4392724027","doi":"https://doi.org/10.1158/0008-5472.c.6510510"},"language":"en","primary_location":{"id":"doi:10.1158/0008-5472.c.6510510","doi":"https://doi.org/10.1158/0008-5472.c.6510510","is_oa":true,"landing_page_url":"https://doi.org/10.1158/0008-5472.c.6510510","pdf_url":null,"source":null,"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"acceptedVersion","is_accepted":true,"is_published":false,"raw_source_name":"American Association for Cancer Research","raw_type":"posted-content"},"volume":null,"type":"other","indexed_in":["crossref"],"open_access":{"is_oa":true,"oa_status":"gold","oa_url":"https://doi.org/10.1158/0008-5472.c.6510510","any_repository_has_fulltext":null},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5008451208","display_name":"Claudia Capparelli","orcid":"https://orcid.org/0000-0001-9834-8539","observed_orcids":["https://orcid.org/0000-0001-9834-8539"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Claudia Capparelli","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5085398803","display_name":"Timothy J. Purwin","orcid":"https://orcid.org/0000-0002-7053-8039","observed_orcids":["https://orcid.org/0000-0002-7053-8039"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Timothy J. Purwin","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5085086811","display_name":"Shea A. Heilman","orcid":"https://orcid.org/0000-0003-4337-5446","observed_orcids":["https://orcid.org/0000-0003-4337-5446"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Shea A. Heilman","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5022471130","display_name":"Inna Chervoneva","orcid":"https://orcid.org/0000-0002-9104-4505","observed_orcids":["https://orcid.org/0000-0002-9104-4505"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Inna Chervoneva","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5012659487","display_name":"Peter A. McCue","orcid":"https://orcid.org/0000-0001-9806-0594","observed_orcids":["https://orcid.org/0000-0001-9806-0594"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Peter A. McCue","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5021531753","display_name":"Adam C. Berger","orcid":"https://orcid.org/0000-0003-1192-3276","observed_orcids":["https://orcid.org/0000-0003-1192-3276"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Adam C. Berger","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5048327749","display_name":"Michael A. Davies","orcid":"https://orcid.org/0000-0002-0977-0912","observed_orcids":["https://orcid.org/0000-0002-0977-0912"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Michael A. Davies","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0000-0002-0977-0912","affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5081648218","display_name":"Jeffrey E. Gershenwald","orcid":"https://orcid.org/0000-0003-4519-5369","observed_orcids":["https://orcid.org/0000-0003-4519-5369"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Jeffrey E. Gershenwald","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5037620517","display_name":"Clemens Krepler","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Clemens Krepler","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"last","author":{"id":"https://openalex.org/A5062746446","display_name":"Andrew E. Aplin","orcid":"https://orcid.org/0000-0002-2734-3244","observed_orcids":["https://orcid.org/0000-0002-2734-3244"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Andrew E. Aplin","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]}],"institutions":[],"countries_distinct_count":0,"institutions_distinct_count":0,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":0,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":null,"issue":null,"first_page":null,"last_page":null},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T11533","display_name":"Melanoma and MAPK Pathways","score":1.0,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},"topics":[{"id":"https://openalex.org/T11533","display_name":"Melanoma and MAPK Pathways","score":1.0,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10158","display_name":"Cancer Immunotherapy and Biomarkers","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11173","display_name":"Neurofibromatosis and Schwannoma Cases","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2728","display_name":"Neurology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/mek-inhibitor-resistance","display_name":"MEK inhibitor resistance","score":0.8460000157356262},{"id":"https://openalex.org/keywords/neuregulin-1","display_name":"neuregulin-1","score":0.9290000200271606},{"id":"https://openalex.org/keywords/erbb3-signaling","display_name":"ErbB3 signaling","score":0.9570000171661377},{"id":"https://openalex.org/keywords/erbb2-signaling","display_name":"ErbB2 signaling","score":0.9279999732971191},{"id":"https://openalex.org/keywords/tumor-microenvironment","display_name":"tumor microenvironment","score":0.6840000152587891},{"id":"https://openalex.org/keywords/cancer-associated-fibroblasts","display_name":"cancer-associated fibroblasts","score":0.906000018119812},{"id":"https://openalex.org/keywords/mek-erk-signaling","display_name":"MEK/ERK signaling","score":0.8510000109672546},{"id":"https://openalex.org/keywords/combination-targeted-therapy","display_name":"combination targeted therapy","score":0.6909999847412109},{"id":"https://openalex.org/keywords/patient-derived-xenografts","display_name":"patient-derived xenografts","score":0.7620000243186951}],"concepts":[{"id":"https://openalex.org/C21790070","wikidata":"https://www.wikidata.org/wiki/Q18030215","display_name":"Neuroblastoma RAS viral oncogene homolog","level":5,"score":0.8831226825714111},{"id":"https://openalex.org/C2781249067","wikidata":"https://www.wikidata.org/wiki/Q17142288","display_name":"MEK inhibitor","level":4,"score":0.6324930191040039},{"id":"https://openalex.org/C2777658100","wikidata":"https://www.wikidata.org/wiki/Q180614","display_name":"Melanoma","level":2,"score":0.5558635592460632},{"id":"https://openalex.org/C207583985","wikidata":"https://www.wikidata.org/wiki/Q128723","display_name":"Wild type","level":4,"score":0.48683708906173706},{"id":"https://openalex.org/C502942594","wikidata":"https://www.wikidata.org/wiki/Q3421914","display_name":"Cancer research","level":1,"score":0.4811590909957886},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.37951111793518066},{"id":"https://openalex.org/C86803240","wikidata":"https://www.wikidata.org/wiki/Q420","display_name":"Biology","level":0,"score":0.2980813980102539},{"id":"https://openalex.org/C57074206","wikidata":"https://www.wikidata.org/wiki/Q14197552","display_name":"MAPK/ERK pathway","level":3,"score":0.19688650965690613},{"id":"https://openalex.org/C501734568","wikidata":"https://www.wikidata.org/wiki/Q42918","display_name":"Mutation","level":3,"score":0.18767377734184265},{"id":"https://openalex.org/C54355233","wikidata":"https://www.wikidata.org/wiki/Q7162","display_name":"Genetics","level":1,"score":0.12315961718559265},{"id":"https://openalex.org/C143065580","wikidata":"https://www.wikidata.org/wiki/Q3285695","display_name":"Mutant","level":3,"score":0.11387351155281067},{"id":"https://openalex.org/C11960822","wikidata":"https://www.wikidata.org/wiki/Q242736","display_name":"Phosphorylation","level":2,"score":0.09086701273918152},{"id":"https://openalex.org/C104317684","wikidata":"https://www.wikidata.org/wiki/Q7187","display_name":"Gene","level":2,"score":0.08878371119499207},{"id":"https://openalex.org/C2781187634","wikidata":"https://www.wikidata.org/wiki/Q20969980","display_name":"KRAS","level":4,"score":0.07062000036239624}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1158/0008-5472.c.6510510","doi":"https://doi.org/10.1158/0008-5472.c.6510510","is_oa":true,"landing_page_url":"https://doi.org/10.1158/0008-5472.c.6510510","pdf_url":null,"source":null,"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"acceptedVersion","is_accepted":true,"is_published":false,"raw_source_name":"American Association for Cancer Research","raw_type":"posted-content"}],"best_oa_location":{"id":"doi:10.1158/0008-5472.c.6510510","doi":"https://doi.org/10.1158/0008-5472.c.6510510","is_oa":true,"landing_page_url":"https://doi.org/10.1158/0008-5472.c.6510510","pdf_url":null,"source":null,"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"acceptedVersion","is_accepted":true,"is_published":false,"raw_source_name":"American Association for Cancer Research","raw_type":"posted-content"},"sustainable_development_goals":[{"score":0.98580002784729,"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being"}],"sustainable_development_goals_aurora":[{"score":0.46000000834465027,"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W2885459183","https://openalex.org/W7062111305","https://openalex.org/W2887772017","https://openalex.org/W4392687156","https://openalex.org/W1972304383","https://openalex.org/W1909910581","https://openalex.org/W2562718573","https://openalex.org/W2104581309","https://openalex.org/W2333520621","https://openalex.org/W2125883153"],"abstract_inverted_index":{"Abstract":[0],"MEK\u2013ERK1/2":[1],"signaling":[2,114,131],"is":[3,44],"elevated":[4],"in":[5,57,93,107,149,161,179,193,238],"melanomas":[6,73,223],"that":[7,75,126],"are":[8,18,202],"wild-type":[9],"for":[10,39,186,199,231],"both":[11,162],"BRAF":[12],"and":[13,32,67,86,132,140,151,165,182,227],"NRAS":[14],"(WT/WT),":[15],"but":[16],"patients":[17,40,194],"insensitive":[19],"to":[20,29,54,95,104,135,157,224],"MEK":[21,55,105,119,137,155,188,225,233],"inhibitors.":[22],"Stromal-derived":[23],"growth":[24,90,160],"factors":[25,91],"may":[26],"mediate":[27],"resistance":[28,94,103,134,178],"targeted":[30,37,96,176,205],"inhibitors,":[31,97],"optimizing":[33],"the":[34,144,154,218],"use":[35],"of":[36,71,78,147,175,220],"inhibitors":[38,106,189,226,234],"with":[41,83,153,190,195,235],"WT/WT":[42,58,72,109,180,196],"melanoma":[43,110,181],"a":[45,136,184,212,229],"clinical":[46],"unmet":[47],"need.":[48],"Here,":[49],"we":[50],"studied":[51],"adaptive":[52],"responses":[53],"inhibition":[56],"cutaneous":[59,197],"melanoma.":[60],"The":[61],"Cancer":[62,241],"Genome":[63],"Atlas":[64],"data":[65],"set":[66],"tumor":[68,159,172],"microarray":[69],"studies":[70,124],"showed":[74],"high":[76],"levels":[77],"neuregulin-1":[79],"(NRG1)":[80],"were":[81],"associated":[82],"stromal":[84],"content":[85],"ErbB3":[87],"signaling.":[88],"Of":[89],"implicated":[92],"NRG1":[98,128,148,216],"was":[99,115],"effective":[100,204],"at":[101],"mediating":[102],"patient-derived":[108,166],"cells.":[111],"Furthermore,":[112],"ErbB3/ErbB2":[113,130],"adaptively":[116],"upregulated":[117],"following":[118],"inhibition.":[120],"Patient-derived":[121],"cancer-associated":[122],"fibroblast":[123],"demonstrated":[125],"stromal-derived":[127],"activated":[129],"enhanced":[133],"inhibitor.":[138],"ErbB3-":[139],"ErbB2-neutralizing":[141],"antibodies":[142,192,237],"blocked":[143],"protective":[145],"effects":[146],"vitro":[150],"cooperated":[152],"inhibitor":[156,177],"delay":[158],"cell":[163],"line":[164],"xenograft":[167],"models.":[168],"These":[169],"results":[170],"highlight":[171],"microenvironment":[173],"regulation":[174],"provide":[183],"rationale":[185,230],"combining":[187,232],"anti-ErbB3/ErbB2":[191],"melanoma,":[198],"whom":[200],"there":[201],"no":[203],"therapy":[206],"options.":[207],"Significance:":[208],"This":[209],"work":[210],"suggests":[211],"mechanism":[213],"by":[214],"which":[215],"regulates":[217],"sensitivity":[219],"WT":[221],"NRAS/BRAF":[222],"provides":[228],"anti-ErbB2/ErbB3":[236],"these":[239],"tumors.":[240],"Res;":[242],"78(19);":[243],"5680\u201393.":[244],"\u00a92018":[245],"AACR.":[246]},"counts_by_year":[],"updated_date":"2026-08-21T09:56:20.448147","created_date":"2024-03-13T00:00:00"}